COYA
Coya Therapeutics, Inc.Healthcare·Biotechnology
$4.82
$88M market cap
Revenue
$4.2M
Free Cash Flow
$-7.2M
Rev Growth
+0.0%
FCF Margin
-171.3%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Scl
2-Year Price History
$4.81-33.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.3 | -7.6 | -7.6 | -7.2 | -6.2 | -6.2 | -0.0 | 50,725 | 0.0 | 16.7 | -0.1% | -- | -- |
| Act | 2025-Q4 | 4.0 | -6.0 | -6.0 | -5.7 | -1.0 | -1.0 | -0.0 | 46.8 | 0.0 | 16.7 | -172.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$4.82
Market Cap$88M
Enterprise Value$-50.6B
P/S Ratio20.8x
P/FCF--
EV/FCF--
FCF Margin (TTM)-171.3%
FCF Yield-8.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$4.2M
Net Income$-12.9M
Free Cash Flow$-7.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin-324.2%
Net Margin-306.7%
FCF Margin-171.3%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-86.3%
WC Change % Rev22491.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.8M
Days to Cover5.7
Change (vs Prior)+6.9%
Need at least 2 settlement dates for chart
Employees
Headcount8
Revenue / Employee$526,393
Gross Profit / Employee$526,042
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
29.1%(+4.2% YoY)
46 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.8%(-1.7% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.2%(-0.4% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| DME Capital Management, LP | $9.2M | $7.79 | +$1.2M | +$2.7M | -1.4% | $3.19B |
| AIGH Capital Management LLC | $3.8M | $5.87 | +$0 | −$821K | +0.8% | $488M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $3.3M | $3.94 | +$3.3M | +$3.3M | — | $4.04T |
| Alyeska Investment Group, L.P. | $3.2M | $5.80 | +$0 | +$3.2M | -0.5% | $35.33B |
| Prosight Management, LP | $1.7M | $3.94 | +$1.7M | +$1.7M | -16.0% | $610M |
| CM Management, LLC | $1.5M | $5.31 | +$99K | +$690K | -4.4% | $120M |
| PRIVATE MANAGEMENT GROUP INC | $1.5M | $5.35 | +$350K | +$1.5M | -0.5% | $3.47B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $920K | $5.51 | +$140K | +$306K | +2.3% | $1.61T |
| MARSHALL WACE, LLP | $890K | $5.78 | +$2K | +$890K | +0.6% | $92.71B |
| VANGUARD FIDUCIARY TRUST COPassive | $551K | $3.94 | +$551K | +$551K | — | $395.83B |
| RENAISSANCE TECHNOLOGIES LLC | $410K | $5.19 | +$146K | +$362K | +1.2% | $63.91B |
| PRELUDE CAPITAL MANAGEMENT, LLC | $399K | $4.21 | +$193K | +$258K | +1.4% | $1.30B |
| JBF Capital, Inc. | $394K | $5.80 | +$0 | +$394K | +1.6% | $674M |
| DIMENSIONAL FUND ADVISORS LPPassive | $377K | $4.54 | +$254K | +$377K | -0.4% | $480.92B |
| MORGAN STANLEY | $338K | $5.16 | +$127K | +$311K | -0.3% | $1.65T |
| BlackRock, Inc.Passive | $326K | $6.21 | +$14K | −$4K | -0.2% | $5.69T |
| STATE STREET CORPPassive | $314K | $7.86 | +$41K | +$125K | -0.2% | $2.89T |
| 683 Capital Management, LLC | $276K | $5.80 | −$40K | +$276K | -2.2% | $1.02B |
| XTX Topco Ltd | $187K | $5.22 | +$56K | +$187K | -1.9% | $5.74B |
| JONES FINANCIAL COMPANIES LLLP | $178K | $4.41 | +$157K | +$178K | -0.1% | $208.07B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.69%
avg per quarter
Holders (ex-self)
-1.64%
excl. this stock
Buyers (this Q)
-10.46%
18 buyers · $0.01B in
Sellers (this Q)
-0.16%
11 sellers · $0.00B out
alpha coverage: 88% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+11.7%
how holders react when this stock falls
On quiet Qs
+9.3%
−10% to +10% baseline
On rallies (+10%+)
+4.5%
how they react when this stock rises
Holders' portfolio flow this Q
+8.2%
inflows — adds are organic
Sellers' portfolio flow this Q
+1.1%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
+3.1%
Holder mid (any stock)
-5.0%
Holder rally (any stock)
-10.8%
Biggest decreases this quarter
AWM Investment Company, Inc.exited−$4.2MSUSQUEHANNA INTERNATIONAL GROUP, LLP−$337Kα-0.6BANK OF AMERICA CORP /DE/exited−$231KWalleye Capital LLCexited−$215KOMERS ADMINISTRATION Corpexited−$200KTrexquant Investment LPexited−$145KMILLENNIUM MANAGEMENT LLCexited−$121KGSA CAPITAL PARTNERS LLPexited−$120KQube Research & Technologies Ltdexited−$119KLantern Wealth Advisors, LLCexited−$103K
New buyers this quarter
Top-5 holders · 66.1%
DME Capital Management, LP--
AIGH Capital Management LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Alyeska Investment Group, L.P.--
Prosight Management, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
DME Capital Management, LP2.3MGREENLIGHT CAPITAL INC—AIGH Capital Management LLC975KAlyeska Investment Group, L.P.800KAWM Investment Company, Inc.—CM Management, LLC375KProsight Management, LP420KPRIVATE MANAGEMENT GROUP INC369KMARSHALL WACE, LLP226KRAYMOND JAMES & ASSOCIATES—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (1 analysts)$17.0025270.0%
Current Price$4.82
Analyst Ratings
5
Buy: 5Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
48.2%retail+3.7pp
12.2%dark-0.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Coya Therapeutics, Inc.: A Clinical Cash-Incinerator Masking Burn with Aggressive Revenue Catch-Ups
Overall Risk
8/10
Fraud
4/10
Dilution
9/10
Insolvency
7/10
Earnings Overstated
6/10
Hidden Liabilities
5/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
6/10